JP2020524174A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524174A5 JP2020524174A5 JP2019571410A JP2019571410A JP2020524174A5 JP 2020524174 A5 JP2020524174 A5 JP 2020524174A5 JP 2019571410 A JP2019571410 A JP 2019571410A JP 2019571410 A JP2019571410 A JP 2019571410A JP 2020524174 A5 JP2020524174 A5 JP 2020524174A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- mutane
- wild
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 108010002350 Interleukin-2 Proteins 0.000 claims 15
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims 10
- 238000006467 substitution reaction Methods 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 108700004922 F42A Proteins 0.000 claims 2
- 102220495631 Putative uncharacterized protein LOC645739_F42A_mutation Human genes 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102220427331 c.274A>T Human genes 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 102200142011 rs121909050 Human genes 0.000 claims 2
- 102200131576 rs121912452 Human genes 0.000 claims 2
- 102200158049 rs387906619 Human genes 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102220505697 Palmitoyl-protein thioesterase 1_Y45F_mutation Human genes 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 102200041867 rs121918148 Human genes 0.000 claims 1
- 102220281620 rs551111938 Human genes 0.000 claims 1
- 229940121497 sintilimab Drugs 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023211159A JP7747716B2 (ja) | 2017-06-19 | 2023-12-14 | Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法 |
| JP2025155111A JP2026001033A (ja) | 2017-06-19 | 2025-09-18 | Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762521957P | 2017-06-19 | 2017-06-19 | |
| US62/521,957 | 2017-06-19 | ||
| US201862679687P | 2018-06-01 | 2018-06-01 | |
| US62/679,687 | 2018-06-01 | ||
| PCT/IB2018/000760 WO2018234862A1 (en) | 2017-06-19 | 2018-06-19 | Uses and methods for il-2 superagonists, agonists, and fusions thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023211159A Division JP7747716B2 (ja) | 2017-06-19 | 2023-12-14 | Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020524174A JP2020524174A (ja) | 2020-08-13 |
| JP2020524174A5 true JP2020524174A5 (enExample) | 2021-07-29 |
| JP7433051B2 JP7433051B2 (ja) | 2024-02-19 |
Family
ID=64737001
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571410A Active JP7433051B2 (ja) | 2017-06-19 | 2018-06-19 | Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法 |
| JP2023211159A Active JP7747716B2 (ja) | 2017-06-19 | 2023-12-14 | Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法 |
| JP2025155111A Pending JP2026001033A (ja) | 2017-06-19 | 2025-09-18 | Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023211159A Active JP7747716B2 (ja) | 2017-06-19 | 2023-12-14 | Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法 |
| JP2025155111A Pending JP2026001033A (ja) | 2017-06-19 | 2025-09-18 | Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11542312B2 (enExample) |
| EP (1) | EP3641814A4 (enExample) |
| JP (3) | JP7433051B2 (enExample) |
| CN (1) | CN111201035A (enExample) |
| AU (2) | AU2018287317B2 (enExample) |
| CA (2) | CA3291498A1 (enExample) |
| WO (1) | WO2018234862A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| JP6592505B2 (ja) | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| AU2018287317B2 (en) | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
| KR102777151B1 (ko) | 2017-11-21 | 2025-03-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 인터루킨-2의 부분 효능제 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CA3094329A1 (en) * | 2018-03-19 | 2020-02-20 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| US12522640B2 (en) * | 2018-07-24 | 2026-01-13 | BioNTech SE | IL2 agonists |
| DK3880186T3 (da) | 2018-11-14 | 2024-06-03 | Regeneron Pharma | Intralæsional administration af pd-1-hæmmere til behandling af hudcancer |
| CN113924311A (zh) * | 2019-01-07 | 2022-01-11 | 印希比股份有限公司 | 包含修饰的il-2多肽的多肽及其用途 |
| US11529402B2 (en) | 2019-01-14 | 2022-12-20 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| SG11202108089SA (en) * | 2019-02-28 | 2021-08-30 | Regeneron Pharma | Administration of pd-1 inhibitors for treating skin cancer |
| CN119350468A (zh) * | 2019-03-29 | 2025-01-24 | 居里研究所 | 具有经修饰的生物活性的白介素-2变体 |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| JP7778571B2 (ja) * | 2019-06-05 | 2025-12-02 | アッシャー バイオセラピューティクス， インコーポレイテッド | 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体 |
| CN110256583B (zh) * | 2019-07-11 | 2022-05-20 | 中国科学院生物物理研究所 | 一种il-2突变体与抗体的融合蛋白及其应用 |
| WO2021016194A1 (en) | 2019-07-19 | 2021-01-28 | Racaniello Vincent R | Second generation seneca valley virus oncolytic therapy: compositions and methods thereof |
| AU2020329933A1 (en) * | 2019-08-15 | 2022-03-24 | Cytimm Therapeutics, Inc. | Modified interleukin 2 (IL-2) polypeptides, conjugates and uses thereof |
| WO2021055697A2 (en) * | 2019-09-18 | 2021-03-25 | The Regents Of The University Of California | Immunoactive microparticles and uses thereof |
| US20220403026A1 (en) * | 2019-09-18 | 2022-12-22 | The Regents Of The University Of California | Implantable scaffolds and uses thereof for immunotherapy and other uses |
| WO2021055660A1 (en) * | 2019-09-18 | 2021-03-25 | The Regents Of The University Of California | Protein producing nanoliposomes and uses thereof |
| BR112022006926A2 (pt) | 2019-10-11 | 2022-07-05 | Tilt Biotherapeutics Oy | Vetor de vírus oncolítico que codifica o polipeptídeo variante de interleucina 2 (vil-2) |
| KR102400884B1 (ko) * | 2019-11-15 | 2022-05-23 | 주식회사 제넥신 | 변형된 인터루킨-7 및 인터루킨-2를 포함하는 융합단백질 및 이의 용도 |
| IL293978A (en) | 2019-12-20 | 2022-08-01 | Regeneron Pharma | New il2 agonists and methods of using them |
| MX2022008547A (es) * | 2020-01-09 | 2022-08-10 | Pfizer | Virus de vacuna recombinante. |
| KR20220140514A (ko) | 2020-01-10 | 2022-10-18 | 브라이트 피크 테라퓨틱스 아게 | 변형된 il-2 폴리펩타이드 및 그의 용도 |
| CN115362168A (zh) * | 2020-01-14 | 2022-11-18 | 辛德凯因股份有限公司 | 偏向化il2突变蛋白方法和组合物 |
| MX2022008770A (es) | 2020-01-14 | 2022-10-07 | Synthekine Inc | Muteinas de la il2. |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| AR121713A1 (es) | 2020-03-31 | 2022-06-29 | Hanmi Pharm Ind Co Ltd | Nuevos análogos de il-2 inmunoestimulantes |
| KR20230010251A (ko) | 2020-05-13 | 2023-01-18 | 보넘 테라퓨틱스, 인크. | 단백질 복합체의 조성물 및 그의 사용 방법 |
| US20230226203A1 (en) * | 2020-06-18 | 2023-07-20 | Proviva Therapeutics (Hong Kong) Limited | Activatable procytokines |
| EP4172216A4 (en) * | 2020-06-24 | 2024-12-04 | Medicenna Therapeutics, Inc. | BIFUNCTIONAL SUPERKINE AND USES THEREOF |
| JP7819944B2 (ja) * | 2020-07-09 | 2026-02-25 | ユーティレックス カンパニー リミテッド | Ｉｌ－２バリアント |
| MX2023000734A (es) * | 2020-07-14 | 2023-02-13 | Pfizer | Virus vaccinia recombinante. |
| KR20230060514A (ko) * | 2020-09-01 | 2023-05-04 | 다케다 야쿠힌 고교 가부시키가이샤 | 인터루킨-2 뮤테인 및 이의 용도 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| WO2022135666A1 (en) * | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022159508A1 (en) * | 2021-01-19 | 2022-07-28 | Seneca Therapeutics, Inc. | Armed seneca valley virus oncolytic therapy compositions and methods thereof |
| WO2022174101A1 (en) * | 2021-02-12 | 2022-08-18 | Synthorx, Inc. | Skin cancer combination therapy with il-2 conjugates and cemiplimab |
| WO2022245500A1 (en) | 2021-05-19 | 2022-11-24 | Asher Biotherapeutics, Inc. | Il-21 polypeptides and targeted constructs |
| WO2022251070A1 (en) * | 2021-05-27 | 2022-12-01 | Innovative Cellular Therapeutics Holdings, Ltd. | Modified chimeric antigen receptor and use thereof |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| EP4376870A4 (en) * | 2021-07-28 | 2025-07-23 | Anwita Biosciences Inc | INTERLEUKIN-2 MUTEINS, FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS |
| JP7849832B2 (ja) * | 2021-08-06 | 2026-04-22 | 国立大学法人 長崎大学 | がんの治療剤 |
| US20240350589A1 (en) | 2021-08-13 | 2024-10-24 | Cytune Pharma | Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer |
| CN115838424A (zh) * | 2021-09-22 | 2023-03-24 | 上海康岱生物医药技术股份有限公司 | 靶向tigit的单克隆抗体 |
| CN118555973A (zh) * | 2021-11-17 | 2024-08-27 | 豪夫迈·罗氏有限公司 | 蛋白质复合物的组合物及其使用方法 |
| AU2023226512A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
| WO2024026449A2 (en) * | 2022-07-28 | 2024-02-01 | Proviva Therapeutics (Hong Kong) Limited | Il-2 procytokine antibody fusion proteins |
| US20260226125A1 (en) * | 2022-09-14 | 2026-08-06 | Medicenna Therapeutics Inc. | Il-2 superantagonists constructs, methods and uses thereof |
| JP2026501323A (ja) * | 2022-12-22 | 2026-01-14 | アナヴェオン アーゲー | Ｉｌ－２融合タンパク質 |
| EP4431525A1 (en) * | 2023-03-16 | 2024-09-18 | Anaveon AG | Il-2 fusion protein |
| WO2024216089A1 (en) * | 2023-04-13 | 2024-10-17 | Bolt Biotherapeutics, Inc. | Anti-dectin-2 antibody combination therapy |
| CN119613562A (zh) * | 2023-09-14 | 2025-03-14 | 重庆精准生物技术有限公司 | 细胞因子融合蛋白及其应用 |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816249A (en) | 1981-11-17 | 1989-03-28 | The Board Of Trustees Of The Leland Stanford Junior University | Monoclonal anti-idiotype antibodies |
| EP0091539B2 (en) | 1982-03-31 | 1996-11-27 | Ajinomoto Co., Inc. | Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5068177A (en) | 1983-12-28 | 1991-11-26 | Scripps Clinic And Research Foundation | Anti-idiotype antibodies induced by synthetic polypeptides |
| US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
| US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| US4656132A (en) | 1984-03-28 | 1987-04-07 | Cetus Corporation | Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria |
| US4530787A (en) | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
| US4572798A (en) | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
| US4748234A (en) | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4931543A (en) | 1987-05-11 | 1990-06-05 | Cetus Corporation | Process for recovering microbially produced interleukin-2 |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5227159A (en) | 1989-01-31 | 1993-07-13 | Miller Richard A | Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies |
| NZ234674A (en) | 1989-08-02 | 1992-02-25 | Seragen Inc | Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| EP1757695A3 (en) | 1992-11-05 | 2008-02-27 | Sloan Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
| US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| US6451308B1 (en) | 1996-04-26 | 2002-09-17 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
| US5856445A (en) | 1996-10-18 | 1999-01-05 | Washington University | Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator |
| US6645490B2 (en) | 1998-03-02 | 2003-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| WO2001010912A1 (en) | 1999-08-09 | 2001-02-15 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US6399857B1 (en) * | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
| WO2001027156A1 (en) | 1999-10-08 | 2001-04-19 | Curagen Corporation | Interleukin-2 like protein and nucleic acids encoding same |
| WO2001036650A2 (en) | 1999-11-15 | 2001-05-25 | Onyx Pharmaceuticals, Inc. | An oncolytic adenovirus |
| AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| EP1454138B1 (en) | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| US20060147420A1 (en) | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
| US6894527B1 (en) | 2003-05-12 | 2005-05-17 | Xilinx, Inc. | Evolved circuits for bitstream protection |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| KR20070003934A (ko) | 2004-03-05 | 2007-01-05 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템 |
| CN100361710C (zh) * | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| ES2432141T3 (es) | 2005-01-27 | 2013-11-29 | Novartis Vaccines And Diagnostics, Inc. | Procedimientos para tratar carcinoma de células renales |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2008039173A2 (en) | 2005-09-09 | 2008-04-03 | Government Of The United States Of Amercica, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for inhibiting cell death or enhancing cell proliferation |
| WO2009046104A1 (en) * | 2007-10-01 | 2009-04-09 | University Of Miami | Aptamer-targeted sirna to prevent attenuation or suppression of t cell function |
| EP2057972A1 (en) | 2007-11-07 | 2009-05-13 | N.V. Organon | Intrauterine deposit |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010031185A1 (en) | 2008-09-19 | 2010-03-25 | Protox Therapeutics Inc. | Treating cancer stem cells using targeted cargo proteins |
| US20100183545A1 (en) | 2008-10-14 | 2010-07-22 | The United States Of America, As Represented By The Secretary, | Targeted cargo protein combination therapy |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010085495A1 (en) | 2009-01-21 | 2010-07-29 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| AU2010216152B2 (en) | 2009-02-17 | 2015-05-14 | Ucb Biopharma Sprl | Antibody molecules having specificity for human OX40 |
| CU23734A1 (es) | 2009-11-27 | 2011-11-15 | Centro Inmunologia Molecular | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| US20120213771A1 (en) | 2010-04-13 | 2012-08-23 | Celldex Therapeutics Inc. | Antibodies that bind human cd27 and uses thereof |
| JP6002659B2 (ja) | 2010-04-13 | 2016-10-05 | セルデックス・セラピューティクス・インコーポレイテッド | ヒトｃｄ２７に結合する抗体およびその使用 |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| US20160354472A1 (en) | 2010-10-22 | 2016-12-08 | Protox Therapeutics Corp. | Use of human serum albumin to decrease antigenicity of therapeutic proteins |
| CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| WO2012119093A1 (en) * | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| FI20115914L (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| US9810692B2 (en) * | 2012-10-26 | 2017-11-07 | Institut Gustave Roussy | Methods for predicting the sensitivity of a subject to immunotherapy |
| IL305629A (en) | 2013-02-15 | 2023-11-01 | Univ California | Chimeric antigen receptor and methods of using it |
| TWI888366B (zh) | 2013-07-16 | 2025-07-01 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法 |
| CN105722860A (zh) * | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
| US10711272B2 (en) * | 2014-01-21 | 2020-07-14 | City Of Hope | CTLA-4 aptamer siRNA species |
| ES2959480T3 (es) | 2014-02-07 | 2024-02-26 | Univ Mcmaster | Acoplador de células T - antígeno trifuncional y métodos y usos del mismo |
| PT3134123T (pt) | 2014-02-21 | 2021-03-22 | Nektar Therapeutics India Pvt Ltd | Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1 |
| JP6592505B2 (ja) * | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
| ES2774380T3 (es) * | 2014-08-29 | 2020-07-20 | Hoffmann La Roche | Politerapia de inmunocitocinas de variante de IL-2 dirigida a tumor y anticuerpos frente a PD-L1 humano |
| CN113698497A (zh) * | 2014-12-05 | 2021-11-26 | 纪念斯隆-凯特琳癌症中心 | 靶向b-细胞成熟抗原的嵌合抗原受体及其用途 |
| AU2016229189A1 (en) | 2015-03-06 | 2017-09-21 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind TIM3 |
| WO2016145085A2 (en) | 2015-03-09 | 2016-09-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
| WO2016146894A1 (en) * | 2015-03-17 | 2016-09-22 | Tilt Biotherapeutics Oy | Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto |
| WO2016176639A1 (en) * | 2015-04-30 | 2016-11-03 | University Of Southern California | Secretory tnt car cell immunotherapy |
| JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗ｐｄ−１抗体及びその使用方法 |
| EP3387155A4 (en) | 2015-12-10 | 2019-06-12 | Definiens AG | METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY |
| MX2018010485A (es) | 2016-03-04 | 2019-01-10 | Jn Biosciences Llc | Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit). |
| AU2018287317B2 (en) | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
| WO2019051204A1 (en) | 2017-09-08 | 2019-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER |
| WO2019239213A2 (en) | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| WO2019232523A1 (en) | 2018-06-01 | 2019-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof |
| CA3098930A1 (en) | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| WO2020160639A1 (en) | 2019-02-07 | 2020-08-13 | Medicenna Therapeutics, Inc. | Il-4r as a biomarker in cancer |
| US12702710B2 (en) | 2020-10-12 | 2026-08-11 | Medicenna Therapeutics Inc. | Combination therapy of MDNA55 and a vascular endothelial growth factor a (VEGF-A) |
-
2018
- 2018-06-19 AU AU2018287317A patent/AU2018287317B2/en active Active
- 2018-06-19 CN CN201880053864.6A patent/CN111201035A/zh active Pending
- 2018-06-19 WO PCT/IB2018/000760 patent/WO2018234862A1/en not_active Ceased
- 2018-06-19 EP EP18820803.7A patent/EP3641814A4/en active Pending
- 2018-06-19 CA CA3291498A patent/CA3291498A1/en active Pending
- 2018-06-19 JP JP2019571410A patent/JP7433051B2/ja active Active
- 2018-06-19 US US16/012,733 patent/US11542312B2/en active Active
- 2018-06-19 CA CA3067909A patent/CA3067909C/en active Active
-
2022
- 2022-08-02 US US17/816,823 patent/US12338269B2/en active Active
-
2023
- 2023-12-14 JP JP2023211159A patent/JP7747716B2/ja active Active
-
2024
- 2024-09-20 AU AU2024219911A patent/AU2024219911A1/en active Pending
-
2025
- 2025-05-19 US US19/212,027 patent/US20260035427A1/en active Pending
- 2025-09-18 JP JP2025155111A patent/JP2026001033A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023532273A5 (enExample) | ||
| Wei et al. | Current landscape and future directions of bispecific antibodies in cancer immunotherapy | |
| Chang et al. | Combination therapy with bispecific antibodies and PD-1 blockade enhances the antitumor potency of T cells | |
| Wang et al. | The state of the art of bispecific antibodies for treating human malignancies | |
| JP2024099850A5 (enExample) | ||
| Klein et al. | Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines | |
| JP6961897B2 (ja) | 癌治療のためのｔ細胞活性化及び／又はチェックポイント阻害剤を組み合わせたペプチド及びペプチド模倣物 | |
| JP2009505676A5 (enExample) | ||
| JP2021522162A5 (enExample) | ||
| Xu et al. | Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody | |
| JP2020055853A5 (enExample) | ||
| CA3125193A1 (en) | Claudin18.2 binding moieties and uses thereof | |
| JP2019110906A5 (enExample) | ||
| JP2018070648A5 (enExample) | ||
| JP2020193210A5 (enExample) | ||
| JP2018501197A5 (enExample) | ||
| JP2020522254A5 (enExample) | ||
| CN117946278A (zh) | 多特异性抗体及其制备和使用方法 | |
| KR20220007584A (ko) | 항-clec2d 항체 및 이의 사용 방법 | |
| JP2017506217A5 (enExample) | ||
| JP2013056885A5 (enExample) | ||
| JP2014530215A5 (enExample) | ||
| JP2025503322A5 (enExample) | ||
| JP2019512207A5 (enExample) | ||
| EP3645049A2 (en) | Multi-specific antibodies and methods of making and using thereof |